• 54,845+ CME Conference Registrations Sold
  • 164,535+ Medical Conferences
  • 297 Specialties
  • 11,711 Organizers
  • 159,489 Speakers
  • 159 Countries
  • 4,847 Cities
Duration: CME/CE Points: Faculty:
-
CME : 12.25

Radiopharmaceutical Therapy in Benign and Malignant Diseases: Radiotheragnostic Practicum is organized by Educational Symposia (ESI) and will be held from Sep 25 - 26, 2020.

This course will now take place as a Live Webcast Only. For more information or to register for the Live Webcast please click here

Registered attendees have access to the archived lectures for 6 months.

Accreditation:
Educational Symposia designates this live activity for a maximum of 12.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Description:
The purpose of this CME course is to deliver to the audience the best practices in the growing field of radiotheragnostics (aka theranostics or theragnostics) for benign and malignant diseases, beginning with the fundamentals and extending to include their advanced clinical applications. The symposium has gathered an outstanding faculty with a vast practical and scientific experience in their designated topics. The overarching goal of each faculty is to arm the audience with the most comprehensive, relevant, and up-to-date knowledge, enabling them to optimally manage common as well as some unusual therapeutic challenges in their own practices. The symposium is intentionally structured to allocate each topic the attention and time that reflects the relative complexity and anticipated need in the nuclear medicine therapy practice. It includs some of the historically established therapies but optimally modernized as well as the recently introduced state-of-the-art modalities into the United States health care. The expert faculty will discuss the optimization of the radiotheragnostic practices for best utilization of various radiopharmaceuticals in contemporary health care delivery systems, both academic and private practice settings.

Educational Objectives
Attendees should, at the completion of this course, be able to:

• The difference between the radiotheragnostic approach and various other concepts guiding the therapeutic delivery of radiation to the target tissues with the objective of improving health outcomes.
• The best therapeutic practice approaches to hyperthyroidism and other benign thyroid diseases, based on evidence and/or sound medical judgment.
• The best therapeutic practice approaches to differentiated thyroid carcinoma, based on evidence and/or sound medical judgment.
• The optimal applications of Y-90 Ibritumomab Tiuxetan for therapy of lymphoma.
• The optimal applications of I-131 Iobenguane to diagnostic imaging and therapy of Pheochromocytoma and Paraganglioma.
• The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.
• The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.
• The optimal approach to diagnostic imaging of recurrent and metastatic prostate cancer.
• The best approach to therapy of skeletal metastatic disease using various Bone-Seeking radiopharmaceuticals.
• The practical examples for evaluation of not listed cancers for radiotheragnostics-based trials.
• Best approaches to building radiotheragnostic practice in academic institutions.
• Best approaches to building radiotheragnostic practice in private practice settings.

For the most updated conference information please visit the webpage: https://www.edusymp.com/product/details/1303

Target Audience

This meeting is designed for nuclear medicine physicians, nuclear radiologists, oncologists, nuclear medicine technologists, health physicists, and radiopharmacists.

Fees

Activity Fee : USD $1,195.00
Interested

Specialties

Oncology, Radiology, Pharmacy and Medicine

Convert
Onsite to Virtual Conference

Market your online event to Million plus Healthcare professionals.

Recommended